Gynecologic cancer

PRIMA Trial Finds QoL Not Reduced Despite Toxicities Observed in Patients with Gynecologic Malignancies
September 27, 2020

A subanalysis of the PRIMA/ENGOT-OV26/GOG-3012 trial found that quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo.

Patients with Gynecologic Cancer May Not be at Increased Risk of COVID-19
August 04, 2020

A study of patients with gynecologic cancer and COVID-19 found that neither having cancer nor receiving treatment for it worsened COVID-19 outcomes.

Oral Apixaban May Be Safe Alternative to Subcutaneous Enoxaparin for Thromboprophylaxis
July 27, 2020

Within this study, satisfaction was markedly higher in those treated with apixaban, and adherence rates appeared to be similar between both modalities in women undergoing surgery for gynecologic cancer.